Iborra M, et al. – Given the well-known benefits of immunosuppressants for sustaining remission and preventing flares of inflammatory bowel disease (IBD), researchers conducted this study to determine the optimal timing for their withdrawal. They calculated the risk of relapse and predictors after withdrawal of azathioprine (AZA) monotherapy in patients who sustained deep remission. This study included 95 patients (35 UC and 60 CD). For UC and CD, the mean duration of AZA treatment was 87 and 77 months, respectively. Remission at 5 years was sustained in almost half of the patients in whom AZA was withdrawn. Corticosteroid dependence, previous surgery, timing of initiation, and indication for AZA were identified to better assess the candidates for withdrawal.